is...wondering why God loves us so much?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've watched and read about this historic call so many times throughout the year since. Amazing Job Yak!
nice Griff :) gj!
HAPPY FRIDAY - SSS!
out with small loss...but great in comparison to what couldve been.
Suffocation...from a gap down, to a selloff - where is the breathing room...
lol - i should be TOSd
Griff - Please explain this :)
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=SVNT&mkttype=after
lol!!!
In SVNT - WAY oversold at this point.
Miss you Yak! Still building...
this post is a KEEPER
thank you vog - day by day, we shall see...
There's hope for the brokenhearted
$4 is definately a safe valuation, my thinking goes forth as with Cerezyme already back in the market (post manufacturing issues) when this CVR was determined (they had manufacturing problems) in addition to positive phase results, the guesstimates start to surface of what Lemtrada will generate fiscally etc...but I agree with you don't jump the gun @ $14
Nominal Value of the CVR
The total potential payout per CVR is an aggregate amount of $14.00 over time
Milestone Description of Milestone Payment Trigger Payment (per CVR)
Production Milestone $1.00
? Cerezyme and Fabrazyme production levels in 2011 hit both
of the following thresholds: (a) at least 734,600 units of
Cerezyme are produced (with each unit measured on a “400
Unit Vial Equivalent” basis) and (b) at least 79,000 units of
Fabrazyme are produced (with each unit measured on a
“35-milligram Vial Equivalent” basis)
Approval Milestone $1.00
? Upon U.S. FDA approval of Lemtrada, as long as the
approval occurs on or before March 31, 2014
Sales Milestone 1 $2.00
? Lemtrada sales total $400mm in multiple geographic
markets within a specified period of time following the first
commercial sale of Lemtrada. The $400 sales level is
determined based on aggregating sales achieved in this
specified period in each of the selected geographic markets
Sales Milestone 2 $3.00
? Lemtrada global sales total $1.8 billion within 4 consecutive
quarters. Any quarters used in the achievement of this sales
milestone cannot be used again for the achievement of any
subsequent milestones
Sales Milestone 3 $4.00
? Lemtrada global sales total $2.3 billion within 4 consecutive
quarters. Any quarters used in the achievement of this sales
milestone cannot be used again for the achievement of any
subsequent milestones
Sales Milestone 4 $3.00
? Lemtrada global sales total $2.8 billion within 4 consecutive
quarters
Total Nominal Value of Milestone Payments per CVR $14.00
Please note that there is no assurance that any milestones will be achieved.
Source
Thank you DD, i had read it posted this morning by an article @ this website:
Click Me.
I am looking into the CVR valuation of this ticker and how they came about where to open, i feel with the upcoming phase results due by mid-year, it's valuated on the low-side. I have read the Table reflecting every $1 move for the CVR value, but still feel it had much potential to the upside in (+) data, what do you think?
Tickers GCVRZ SFY
Genzyme’s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial.
Five years’ worth of mid-stage data for Lemtrada (alemtuzumab) showed that 65% of patients were free of clinically-active disease, compared to 27% on Merck’s interferon treatment Rebif.
The data, which was presented at the 63rd Annual Meeting of the American Academy of Neurology, also showed that 72% of patients treated with Lemtrada were relapse-free compared to 41% for Rebif.
Two phase III studies investigating Lemtrada, CARE-MS I and II, are currently ongoing with top-line results expected to be available in the second half of this year.
Lemtrada’s US application has been fast-tracked by the FDA and Genzyme expects to file for US and European approvals in early 2012.
Analysts predict Lemtrada, which is already licensed to treat chronic lymphocytic leukaemia, could make peak annual sales of between $750 million to $2 billion for Genzyme and its new owners Sanofi-Aventis.
Many patients with MS also suffer from visual impairment, and a second abstract presented at the American Academy of Neurology meeting showed Lemtrada was twice as likely to improve vision problems when compared to Rebif.
The drug will face tough competition from Novartis’ oral MS drug Gilenya (fingolimod), which received EMA approval in March and FDA approval last year.
In one key study Gilenya was shown to cut relapses of MS by 52% at one year compared to Rebif and analysts predict blockbuster sales of around $2.5 billion for Novartis’ drug.
Ben Adams
April, we're back down. If there is blockbuster news, tell the ceo to do something, I believe it will continue to fizzle to sub-zero levels and any posting of news, is for more selling off.
Interesting, how did you know news was coming out?
A market sell, is not a way to sell these shares - im just saying since we know this is valued at much more north of $1.90
belch.....
ty! LOL!
GM YAK!!!! & SSS!!!!!!!!
FDA NEWS RELEASE
For Immediate Release: April 6, 2011
Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
FDA approves new treatment for rare form of thyroid cancer
Vandetanib is first drug approved for medullary thyroid cancer
The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.
Thyroid cancer is a cancerous growth of the thyroid gland, which is located in the neck. Medullary thyroid cancer involves specific types of cells that are found in the thyroid gland and can occur spontaneously, or be part of a genetic syndrome.
About 44,600 new thyroid cancer cases were diagnosed in the United States during 2010, and about 1,690 people died from the disease, according to the National Cancer Institute. Medullary thyroid cancer is estimated to represent 3 to 5 percent of all thyroid cancer; its estimated incidence in the United States for 2010 is about 1,300 to 2,200 patients, making it one of the rarer forms of thyroid cancer.
Common symptoms of medullary thyroid cancer may include coughing, difficulty swallowing, enlargement of the thyroid gland, swelling of the neck, a lump on the thyroid, and changes in a person’s voice or hoarseness.
Vandetanib targets medullary thyroid cancer’s ability to grow and expand. There are currently no FDA-approved treatments for this type of cancer. Vandetanib is administered orally on a daily basis.
Vandetanib’s safety and effectiveness were established in a single, randomized international study of 331 patients with late-stage medullary thyroid cancer. Patients in the study were selected to receive vandetanib or placebo (sugar pill).
The study was designed to measure the length of time a patient lived without the individual’s cancer progressing (progression-free survival). Patients who received vandetanib had a longer period of time without disease progression when compared to patients receiving placebo. Median progression-free survival was 16.4 months in the placebo arm and at least 22.6 months in the vandetanib arm. It is too early to determine the median progression-free survival in patients treated with vandetanib or to tell whether they will live longer (overall survival) compared to patients treated with placebo.
“Vandetanib’s approval underscores FDA’s commitment to approving treatments for patients with rare and difficult to treat diseases,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research.
Common side effects occurring from vandetanib use include diarrhea, rash, nausea, high blood pressure, headache, fatigue, decreased appetite, and stomach (abdominal) pain. Serious side effects reported during the study resulted in five deaths in patients treated with vandetanib. Causes of death included breathing complications, heart failure, and a bacterial infection in the blood (sepsis).
Vandetanib was shown to affect the electrical activity of the heart, which in some cases can cause irregular heartbeats that could lead to death. Vandetanib is being approved with a Risk Evaluation and Mitigation Strategy (REMS) to inform health care professionals about these serious heart-related risks. Only health care professionals and pharmacies certified through the vandetanib REMS program, a restricted distribution program, will be able to prescribe and dispense the drug. Patients will also receive an FDA-approved Medication Guide informing them of the potential risks.
Vandetanib is marketed by AstraZeneca Pharmaceuticals LP of Wilmington, Del. There is no trade name established for this drug at this time.
molasses - 6s up!
PURO - down - 68%.
AMIE - down $2.48 cents.!!
strategic to release bad news, usually the case.
yea on a friday night .
i was expecting nothing below $1, this drop is crazy .
OMG 80% LOOK FOR THE BOUNCE!
Resumes @ 530pm - News released, they're selling assets.
and so iz I
20,000,000 bagger, but do we really need to get picky in this case? lol
HW - TGIF.
So, when should we work on the vision of the board? :)
Thank you Vog.
Share Structure (correct me if i'm wrong):
83,000 OS (post split)
333,333 AS (post split)
Penny stock players!!!! 1$ into 20 M !! touche'
AIB resumed.